Eton Pharmaceuticals, Inc.
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
ETON$64.35+14.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Balance Sheets
| September 30, 2026 | December 31, 2025 | |
|---|---|---|
| (Unaudited) | ||
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $55,628 | $25,942 |
| Accounts receivable, net | 26,426 | 11,757 |
| Inventories, net | 11,082 | 15,419 |
| Prepaid expenses and other current assets | 3,646 | 7,463 |
| Total current assets | 96,782 | 60,581 |
| Property and equipment, net | 338 | 326 |
| Intangible assets, net | 44,280 | 30,878 |
| Operating lease right-of-use assets, net | 1,064 | 310 |
| Deferred tax asset | 14,745 | — |
| Other long-term assets, net | 64 | 19 |
| Total assets | $157,273 | $92,114 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $16,499 | $10,976 |
| Short-term debt, net of debt discount | 11,842 | 8,789 |
| Accrued Medicaid rebates | 9,653 | 9,317 |
| Accrued liabilities | 16,101 | 9,408 |
| Total current liabilities | 54,095 | 38,490 |
| Long-term debt, net of current portion, debt discount and accrued exit fees | 11,227 | 21,769 |
| Operating lease liabilities, net of current portion | 1,017 | 460 |
| Other long-term liabilities | 4,011 | 5,241 |
| Total liabilities | 70,350 | 65,960 |
| Commitments and contingencies (Note 13) | ||
| Stockholders’ equity | ||
| Common stock, $0.001 par value; 50,000,000 shares authorized; 28,827,905 and 27,047,061 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively | 29 | 27 |
| Additional paid-in capital | 151,007 | 138,621 |
| Accumulated deficit | (64,113) | (112,494) |
| Total stockholders’ equity | 86,923 | 26,154 |
| Total liabilities and stockholders’ equity | $157,273 | $92,114 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.